2003•International Journal of HematologyRequires access

Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?

Keisuke Miyazawa, J Nishimaki, Tomoko Katagiri, Goro Sashida, Nahoko Shoji, Ken Kawakubo, Akitaka Suzuki, Takashi Shimamoto, Akihiko Gotoh, Yuzuru Kuriyama, Yoshikazu Ito, Tetsuzo Tauchi, Yoshikazu Kawanishi, Yukihiko Kimura, Kazuma Ohyashiki

Open publisher page 12 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Imatinib mesylate, Mesylate, Chronic myelogenous leukemia, Imatinib, Medicine, Hematology, Internal medicine, Pharmacology